RESPITE: switching to riociguat in pulmonary arterial hypertension patients with inadequate response to phosphodiesterase-5 inhibitors

A proportion of pulmonary arterial hypertension (PAH) patients do not reach treatment goals with phosphodiesterase-5 inhibitors (PDE5i). RESPITE investigated the safety, feasibility and benefit of switching from PDE5i to riociguat in these patients. RESPITE was a 24-week, open-label, multicentre, un...

Descripción completa

Detalles Bibliográficos
Autores principales: Hoeper, Marius M., Simonneau, Gérald, Corris, Paul A., Ghofrani, Hossein-Ardeschir, Klinger, James R., Langleben, David, Naeije, Robert, Jansa, Pavel, Rosenkranz, Stephan, Scelsi, Laura, Grünig, Ekkehard, Vizza, Carmine Dario, Chang, MiKyung, Colorado, Pablo, Meier, Christian, Busse, Dennis, Benza, Raymond L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Respiratory Society 2017
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898946/
https://www.ncbi.nlm.nih.gov/pubmed/28889107
http://dx.doi.org/10.1183/13993003.02425-2016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898946/
https://www.ncbi.nlm.nih.gov/pubmed/28889107
http://dx.doi.org/10.1183/13993003.02425-2016

Ejemplares similares